- Home
- MHO vs NAMS Comparison
MHO vs NAMS Comparison
Compare MHO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHO | NAMS |
|---|---|---|
| Founded | 1976 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | MHO | NAMS |
|---|---|---|
| Price | $131.52 | $38.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $160.00 | $46.75 |
| AVG Volume (30 Days) | 199.5K | ★ 938.9K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $4,417,781,000.00 | N/A |
| Revenue This Year | $0.66 | $17.96 |
| Revenue Next Year | $6.97 | $540.65 |
| P/E Ratio | $50.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $103.52 | $16.79 |
| 52 Week High | $158.92 | $42.00 |
Technical Indicators
Market Signals| Indicator | MHO | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 69.61 |
| Support Level | $125.38 | $34.05 |
| Resistance Level | $132.39 | $41.40 |
| Average True Range (ATR) | 4.17 | 2.20 |
| MACD | 0.11 | 0.62 |
| Stochastic Oscillator | 51.68 | 77.33 |
Price Performance
Historical ComparisonAbout MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.